In the past week, SLN stock has gone down by -21.55%, with a monthly decline of -24.51% and a quarterly plunge of -10.90%. The volatility ratio for the week is 7.38%, and the volatility levels for the last 30 days are 4.68% for Silence Therapeutics Plc ADR The simple moving average for the past 20 days is -19.69% for SLN’s stock, with a -31.11% simple moving average for the past 200 days.
Is It Worth Investing in Silence Therapeutics Plc ADR (NASDAQ: SLN) Right Now?
Additionally, the 36-month beta value for SLN is 1.23. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SLN is 39.80M and currently, short sellers hold a 0.89% ratio of that float. The average trading volume of SLN on November 15, 2024 was 175.72K shares.
SLN) stock’s latest price update
Silence Therapeutics Plc ADR (NASDAQ: SLN) has seen a decline in its stock price by -8.27 in relation to its previous close of 15.24. However, the company has experienced a -21.55% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2024-09-08 that Silence Therapeutics focuses on RNA interference therapies, with its lead candidates targeting cardiovascular and hematological diseases via the mRNAi GOLD platform. Zerlasiran, the company’s main value driver, aims to reduce lipoprotein(a) levels, potentially lowering cardiovascular risks in 20-25% of the global population. Divesiran shows promise in early trials for Polycythemia Vera. Early clinical trial data suggests it can effectively regulate red blood cell production.
Analysts’ Opinion of SLN
Many brokerage firms have already submitted their reports for SLN stocks, with Jefferies repeating the rating for SLN by listing it as a “Buy.” The predicted price for SLN in the upcoming period, according to Jefferies is $40 based on the research report published on September 03, 2024 of the current year 2024.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see SLN reach a price target of $67. The rating they have provided for SLN stocks is “Outperform” according to the report published on January 31st, 2024.
SLN Trading at -22.74% from the 50-Day Moving Average
After a stumble in the market that brought SLN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.57% of loss for the given period.
Volatility was left at 4.68%, however, over the last 30 days, the volatility rate increased by 7.38%, as shares sank -24.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.84% lower at present.
During the last 5 trading sessions, SLN fell by -21.55%, which changed the moving average for the period of 200-days by -37.89% in comparison to the 20-day moving average, which settled at $17.41. In addition, Silence Therapeutics Plc ADR saw -19.52% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SLN
Current profitability levels for the company are sitting at:
- -2.71 for the present operating margin
- 0.56 for the gross margin
The net margin for Silence Therapeutics Plc ADR stands at -2.24. The total capital return value is set at -0.28. Equity return is now at value -63.79, with -28.25 for asset returns.
Currently, EBITDA for the company is -49.78 million with net debt to EBITDA at 2.34. When we switch over and look at the enterprise to sales, we see a ratio of 22.73. The receivables turnover for the company is 10.62for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.83.
Conclusion
In conclusion, Silence Therapeutics Plc ADR (SLN) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
